Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway

الملخص EN

Acquired resistance to cisplatin is the most common reason for the failure of cisplatin chemotherapy.

Hederagenin, triterpenoids extracted from ivy leaves, exhibits antitumor activity in various types of cancer.

However, the therapeutic potential of hederagenin in head and neck cancer (HNC) has remained unclear.

Therefore, we examined the effects of hederagenin in cisplatin-resistant HNC cells and characterized its molecular mechanisms of action in this context.

We evaluated the effects of hederagenin treatment on cell viability, apoptosis, reactive oxygen species (ROS) production, glutathione levels, mitochondrial membrane potential (ΔΨm), and protein and mRNA expression in HNC cells.

The antitumor effect of hederagenin in mouse tumor xenograft models was also analyzed.

Hederagenin selectively induced cell death in both cisplatin-sensitive and cisplatin-resistant HNC cells by promoting changes in ΔΨm and inducing apoptosis.

Hederagenin inhibited the Nrf2-antioxidant response element (ARE) pathway and activated p53 in HNC cells, thereby enhancing ROS production and promoting glutathione depletion.

These effects were reversed by the antioxidant trolox.

Hederagenin activated intrinsic apoptotic pathways via cleaved PARP, cleaved caspase-3, and Bax.

The selective inhibitory effects of hederagenin were confirmed in cisplatin-resistant HNC xenograft models.

These data suggest that hederagenin induces cell death in resistant HNC cells via the Nrf2-ARE antioxidant pathway.